TME Pharma Announces New Data From NOX-A12 GLORIA Phase 1/2 Study in Glioblastoma to Be Presented at ASCO Annual Meeting in June 2023

On April 27, 2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), reported that new data from the GLORIA Phase 1/2 clinical trial evaluating NOX-A12 in brain cancer (glioblastoma) will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place in Chicago from June 2-6, 2023 (Press release, TME Pharma, APR 27, 2023, View Source [SID1234630648]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased that the ASCO (Free ASCO Whitepaper) Scientific Program Committee has chosen the GLORIA trial for presentation at this year’s ASCO (Free ASCO Whitepaper) Annual Meeting, which is one of the highest-profile and most selective conferences where researchers from around the world come to learn about clinical trials of promising new cancer therapies. We look forward to sharing these groundbreaking new data and analysis coming from the GLORIA study at the ASCO (Free ASCO Whitepaper) conference," said Aram Mangasarian, CEO of TME Pharma.

Details of Presentation:
Title: Potential predictive biomarker for response to radiotherapy and CXCL12-inhibition in glioblastoma in the phase 1/2 GLORIA trial (abstract #2048)
Presenter: Dr. Frank A. Giordano, Professor and Chair of the Department of Radiation Oncology at the University Medical Center Mannheim, Germany, and the lead investigator of the GLORIA trial.
Session Type: Poster Session
Session Title: Central Nervous System Tumors
Session Date and Time: June 3, 2023, 01:15-04:15pm CST
Registration: To register to the event, please click here

The full abstract will be published online by ASCO (Free ASCO Whitepaper) on May 25, 2023, at 05.00 p.m. EDT (11.00 p.m. CEST). TME Pharma will share the details of the presentation as they become publicly available by the annual meeting organizer.

ASCO is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. Its flagship event, the Annual Meeting, promotes cutting-edge research and attracts more than 40,000 oncology professionals from around the world every year.